Literature DB >> 8448591

Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, Hoe 140.

T Griesbacher1, B Tiran, F Lembeck.   

Abstract

1. In a previous investigation, Hoe 140, a specific and potent bradykinin B2 receptor antagonist, prevented the pancreatic oedema and the hypotension observed during acute experimental pancreatitis; however, it augmented the associated rises in the serum activities of pancreatic enzymes. Therefore, we have now investigated the consequences of the pancreatic oedema for the fate of activated enzymes released into the tissue during the course of acute pancreatitis. 2. Acute oedematous pancreatitis was induced in rats, pretreated with captopril (50 mumol kg-1, i.p.), by hyperstimulation of the exocrine function of the pancreas with the cholecystokinin analogue, caerulein (4 nmol kg-1 h-1, i.v.), for up to 120 min. 3. Pancreatic oedema began to develop 10 min after the start of the caerulein infusion, reached a maximum within about 45 min, and then declined slightly. The development of the oedema parallelled the second phase of the caerulein-induced fall in blood pressure found in earlier experiments. No further extravasation of plasma proteins occurred during the 2nd hour of the caerulein infusion. The oedema formation was completely blocked in animals pretreated with the bradykinin receptor antagonist, Hoe 140 (100 nmol kg-1, s.c.). Pretreatment with aprotinin or soy bean trypsin inhibitor did not result in a significant inhibition of the oedema. 4. The haematocrit of animals with experimental pancreatitis showed a pronounced increase which started 10 min after the start of the caerulein infusion and reached maximal values at 60 min. The changes in haematocrit showed a reduction in total blood volume of 28% due to a 48% loss of plasma. This effect was completely blocked by Hoe 140. 5. In rats with caerulein-induced pancreatitis, there was a time-dependent increase in the activities of amylase and lipase in blood serum as well as in the pancreas. Pretreatment with Hoe 140 greatly augmented the caerulein-induced rise in enzyme activities in blood serum but potently attenuated it in the pancreas. The activities of trypsin in both the blood serum and the pancreas were below or near the limit of detection in all experimental groups.6. It is concluded that the second phase of hypotension in this model of acute pancreatitis is due to the liberation of kinins which cause a massive loss of blood plasma into the pancreas and into the retroperitoneal space. Activated enzymes are trapped in the pancreas, at least in part, by the oedema of the gland. Treatment with Hoe 140 prevents the oedema formation and greatly facilitates the egress of activated enzymes from the pancreas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8448591      PMCID: PMC1907991          DOI: 10.1111/j.1476-5381.1993.tb12817.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  [The problem of therapy of pancreatitis].

Authors:  E WERLE; K TAUBER; W HARTENBACH; M M FORELL
Journal:  Munch Med Wochenschr       Date:  1958-08-29

2.  [Problem of the mechanism of origin of circulatory collapse in acute pancreatic necrosis].

Authors:  M M FORELL
Journal:  Gastroenterologia       Date:  1955

Review 3.  Aetiology and pathogenesis of pancreatitis. (Current concepts).

Authors:  W Creutzfeldt; H Schmidt
Journal:  Scand J Gastroenterol Suppl       Date:  1970

4.  Activation of proteases in cerulein-induced pancreatitis.

Authors:  H Yamaguchi; T Kimura; K Mimura; H Nawata
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

5.  Structural alterations of pancreatic microvasculature in cerulein-induced pancreatitis in the rat.

Authors:  T M Gress; R Arnold; G Adler
Journal:  Res Exp Med (Berl)       Date:  1990

6.  Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis.

Authors:  T Griesbacher; F Lembeck
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

7.  Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis.

Authors:  O Watanabe; F M Baccino; M L Steer; J Meldolesi
Journal:  Am J Physiol       Date:  1984-04

8.  Caerulein-induced acute pancreatitis in rats: changes in glycoprotein-composition of subcellular membrane systems in acinar cells.

Authors:  S Willemer; R Bialek; H Köhler; G Adler
Journal:  Histochemistry       Date:  1990

9.  Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin.

Authors:  R Gamse; P Holzer; F Lembeck
Journal:  Br J Pharmacol       Date:  1980-02       Impact factor: 8.739

10.  Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis.

Authors:  H Harada; H Miyake; K Ochi; J Tanaka; I Kimura
Journal:  Int J Pancreatol       Date:  1991
View more
  12 in total

1.  Attenuation of persistent experimental pancreatitis pain by a bradykinin b2 receptor antagonist.

Authors:  Qingmin Chen; Louis P Vera-Portocarrero; Michael H Ossipov; Marina Vardanyan; Josephine Lai; Frank Porreca
Journal:  Pancreas       Date:  2010-11       Impact factor: 3.327

2.  Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice.

Authors:  E F Grady; S K Yoshimi; J Maa; D Valeroso; R K Vartanian; S Rahim; E H Kim; C Gerard; N Gerard; N W Bunnett; K S Kirkwood
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

3.  Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs.

Authors:  E F Yekebas; H Treede; W T Knoefel; C Bloechle; E Fink; J R Izbicki
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

4.  Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; D Michael Evans
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

5.  Blockade of bradykinin B(2) receptor suppresses acute pancreatitis induced by obstruction of the pancreaticobiliary duct in rats.

Authors:  Mitsuhiro Hirata; Izumi Hayashi; Kuniko Yoshimura; Ken-ichiro Ishii; Kazui Soma; Takashi Ohwada; Akira Kakita; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  Effects of the bradykinin antagonist, icatibant (Hoe 140), on pancreas and liver functions during and after caerulein-induced pancreatitis in rats.

Authors:  T Griesbacher; C Kolbitsch; B Tiran; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

7.  Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.

Authors:  T Griesbacher; I Rainer; B Tiran; B A Peskar
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

8.  Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.

Authors:  Thomas Griesbacher; Irmgard Rainer; Beate Tiran; Edwin Fink; Fred Lembeck; Bernhard A Peskar
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Blood pressure reflexes following activation of capsaicin-sensitive afferent neurones in the biliopancreatic duct of rats.

Authors:  T Griesbacher
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

10.  Ca(2+) signals mediated by bradykinin type 2 receptors in normal pancreatic stellate cells can be inhibited by specific Ca(2+) channel blockade.

Authors:  Oleksiy Gryshchenko; Julia V Gerasimenko; Oleg V Gerasimenko; Ole H Petersen
Journal:  J Physiol       Date:  2015-11-08       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.